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Objectives. We sought to assess the relation between plasma
lipoprotein(a) [Lp(a)] levels, clinical variables and angiographic
coronary artery disease (CAD) in patients with chronic stable
angina.
Background. The relation between plasma Lp(a) levels and the
severity and extent of angiographic CAD has not been studied in
well characterized patients with stable angina pectoris.
Methods. We investigated clinical variables, lipid variables and
angiographic scores in 129 consecutive white patients (43 women)
undergoing coronary angiography for chronic stable angina.
Results. Plasma Lp(a) levels were significantly higher in pa-
tients with than in those without significant angiographic stenoses
(>270%) (372 mg/liter [interquartile range 87 to 884] vs. 105
mg/liter [interquartile range 56 to 366], respectively, p 5 0.002).
This difference remained significant when patients with mild or
severe angiographic disease were compared with those with com-
pletely normal coronary arteries (312 mg/liter [interquartile
range 64 to 864] vs. 116 mg/liter [interquartile range 63 to 366],
respectively, p 5 0.02). However, subset analysis indicated that
this difference achieved statistical significance only in women.
Multiple logistic regression analysis indicated that Lp(a) concen-
tration was independently predictive of significant angiographic
stenoses (adjusted odds ratio [OR] 9.1, 95% confidence interval
[CI] 2.0 to 42.1, p 5 0.006) and remained true even after exclusion
of patients receiving lipid-lowering treatment (n 5 27) (OR 10.4,
95% CI 1.1 to 102.9, p 5 0.05). Lp(a) also had independent
predictive value in a similar analysis using mild or severe
angiographic disease as the outcome variable (OR 11.8, 95% CI
1.5 to 90.8, p 5 0.02).
Conclusions. Our results indicate that elevated plasma Lp(a) is
an independent risk factor for angiographic CAD in chronic stable
angina and may have particular significance in women.
(J Am Coll Cardiol 1998;31:1260–6)
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Apolipoprotein(a) [apo(a)] is a hydrophilic glycoprotein that
shows a remarkable homology with plasminogen (1). It acts as
a competitive inhibitor of tissue-type plasminogen activator
(2–4) and inhibits generation of the thrombolytic enzyme
plasmin (5). Lipoprotein(a) [Lp(a)] is a macromolecular com-
plex found in human plasma that is composed of low density
lipoprotein (LDL) and apo(a). Some investigators (4) have
proposed that Lp(a) may represent a link between the athero-
sclerotic and thrombotic manifestations of coronary artery
disease (CAD). Lp(a) levels are highly heritable (6), and it has
been shown (7) that excess plasma Lp(a) is the most frequent
lipoprotein disorder in families with premature CAD. Raised
plasma Lp(a) also correlates with a history of previous myo-
cardial infarction (MI) (8,9) and is an independent risk factor
for subsequent MI or cardiac death (10–14). Nevertheless,
uncertainty still exists regarding the relation between plasma
Lp(a) and angiographically defined CAD. Some studies have
indicated an association between plasma Lp(a) levels and
angiographic disease severity (15–18), but others have failed to
confirm these findings (19,20). This controversy may be due to
the lack of data regarding clinical status and coronary risk
factors in many such studies. Furthermore, women have fre-
quently been underrepresented, limiting the potential for
analysis of potentially important gender-specific differences. In
the present study, we measured plasma Lp(a) levels in a
consecutive series of well characterized white men and women
undergoing coronary angiography for the assessment of chest
pain consistent with chronic stable angina. This approach
enabled us to perform a careful investigation of the relation
between Lp(a) levels, CAD severity and other clinical variables
in men and women.
Methods
Patients. Over 4-month period (December 1995 through
March 1996), we studied 129 white patients (43 women) from
a consecutive series of 198 patients with chest pain undergoing
diagnostic coronary angiography for investigation of chest pain
consistent with chronic stable angina. Chronic stable angina was
defined as typical exertional chest pain relieved either by rest
or sublingual nitrates, or both, and with no change in symp-
toms in the preceding 3 months. Nonwhite patients were not
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included because of the potential confounding influence of
interracial differences. Patients with the following characteris-
tics were also excluded: significant valvular heart disease (n 5
30); previous coronary artery bypass graft surgery (n 5 17); MI
within the previous 3 months (n 5 6); cancer (n 5 1);
end-stage renal failure (n 5 2); and participation in other
research studies (n 5 14). Clinical details, including previous
MI, conventional risk factors for CAD (smoking, hypertension,
family history of premature cardiovascular disease, diabetes,
hyperlipidemia), menopausal status in women, drug therapy,
blood pressure, height and weight were recorded for all
patients. No patient was receiving niacin therapy, which has
been shown (21) to significantly reduce Lp(a) levels.
Analysis of serum Lp(a) levels. Venous blood samples
were collected from patients in the fasting state immediately
before angiography. Plasma and serum were stored at 270°C
(for ,3 months) for subsequent analysis for Lp(a) levels and
full lipid profile. Lp(a) was measured by a rate nephelometric
method using the Beckman Array 360. The sample was diluted
in Apodiluent and centrifuged before loading on the Array.
The prediluted sample was mixed with rabbit anti-human
antibody (Dako, Denmark). According to standard practice,
the amount of light scattered is measured by nephelometry,
and the scatter signal is converted to a maximal rate of light
scatter or light units. As the antigen concentration increases,
the maximal rate of light scatter increases. Lp(a) concentration
was calculated from rate units by drawing a standard curve and
interpolating the Lp(a) concentration. Within-match precision
for the rate nephelometric method was 1.5% and 1.2% at
Lp(a) values of 158 and 343 mg/liter, respectively (n 5 10 in
each case). Overall precision was 6% (mean 166 mg/liter,
coefficient of variation 6.1% [n 5 33]; mean 343 mg/liter,
coefficient of variation 5.6% [n 5 32], respectively). This
precision is in accord with that reported for other automated
nephelometric methods (22) and compares favorably with that
recently reported for Lp(a) measurements using an ELISA
method (23). The Lp(a) results from the Array method also
agreed well with the results obtained by an immunozyme
ELISA (Deming’s regression: y [Array] 5 0.96 [ELISA] 22.1,
correlation coefficient 0.936 [n 5 68]). Total cholesterol and
triglyceride levels were measured by conventional enzymatic
methods. High density lipoprotein (HDL) cholesterol was
measured by dextran sulfate and magnesium chloride precipi-
tation of LDL cholesterol, followed by cholesterol analysis of
the supernatant using the model 12 Monarch centrifuge ana-
lyzer. LDL cholesterol was determined using the Friedewald
formula.
Coronary angiographic analysis. Diagnostic coronary arte-
riography was carried out using the Judkins technique in all
patients. The right and left coronary arteries were selectively
imaged according to standard views with at least two orthog-
onal projections of any stenotic segments. Angiographic scor-
ing (see later) of each vessel segment was based on the severity
and extent of disease observed in the “most severe” projection,
as is customary in such studies (24,25). Additional nitrate
therapy was not administered routinely before imaging, al-
though 70% of study patients were receiving oral nitrate
therapy. Each angiogram was analyzed independently by two
experienced cardiologists (R.S., J.C.K.) in blinded manner with
regard to clinical and laboratory data. Analysis was performed
according to the vessel and extent of disease scoring system
previously described by Sullivan et al. (26) and utilized in other
similar studies examining the role of Lp(a) in CAD (18). In
summary, the severity and extent of CAD was assessed as follows.
Vessel score. Vessel score ranged from 0 to 3 according to
the number of major epicardial vessels (left anterior descend-
ing, left circumflex and right coronary arteries) with significant
stenoses ($70% lumen diameter stenosis). The left main stem
was regarded as one vessel. Stenosis of the left main stem and
left anterior descending or left circumflex coronary artery, or
both, was counted as two points.
Extent score. The length proportion (0 to 1.0) of each vessel
segment involved by any angiographically visible atheroma was
estimated and multiplied by a predefined weighting factor as
follows: left main stem 5 5; left anterior descending coronary
artery 5 20; main diagonal branch 5 10; first septal perfora-
tor 5 5; left circumflex coronary artery 5 20; obtuse marginal
and posterolateral vessels 5 10; right coronary artery 5 20 and
main posterior descending artery 5 10. If the major vessel
supplying the lateral ventricular wall was a large obtuse
marginal or intermediate vessel, a weighting factor of 20 was
applied to the marginal/intermediate branch and 10 to the left
circumflex artery. When a vessel was occluded and the distal
segments were not filled by collateral flow, the mean extent
score of the remaining vessel was assigned to the unvisualized
segment or segments. The scores for each vessel or branch
were added to give a total score up to a maximum of 100,
representing the estimated percent of atheromatous involve-
ment of the intimal coronary surface. For each scoring system,
the mean of the scores from the two observers was used for
analysis. For the purpose of analysis, the presence of angio-
graphically detectable CAD was defined by an extent score .0.
The interobserver variability (the standard deviation of the
mean unsigned difference between paired estimates) for the
extent score in this study was 4.7%.
Statistical analysis. Baseline characteristics of the study
cohort were compared using the chi-square test. Lp(a) data
were expressed as median (interquartile range) because of the
known skewed distribution of these levels. Other data are
Abbreviations and Acronyms
apo(a) 5 apolipoprotein(a)
CAD 5 coronary artery disease
CI 5 confidence interval
FATS 5 Familial Atherosclerosis Treatment Study
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
Lp(a) 5 lipoprotein(a)
MI 5 myocardial infarction
OR 5 odds ratio
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expressed as mean value 6 SD. The Mann-Whitney U test was
used for two-group comparison of Lp(a), total cholesterol,
LDL cholesterol and triglyceride concentrations. An overall
test for differences between groups of patients classified ac-
cording to coronary angiographic disease score was performed
using the Kruskall-Wallis test; pairwise comparisons were not
performed. Multivariate logistic regression analyses were per-
formed using SAS Release 6.03. The same predictor variables
(i.e., age, gender, hypertension, smoking and lipid parameters
[Lp(a), LDL, HDL and triglycerides]) were used in all logistic
models without stepwise selection. The dependent variable was
either angiographic CAD or extent score (see earlier). The
analysis was performed with inclusion of all patients (n 5 129)
and then repeated with inclusion of only patients not receiving
lipid-lowering therapy (n 5 102). The results of the multivar-
iate analysis are expressed as odds ratios for the comparison of
risk between the 10% and 90% percentiles (with 95% confi-
dence intervals). Significance was defined as a p value ,0.05
for the null hypothesis.
Results
Clinical variables at study entry. The baseline character-
istics, including level of symptoms and conventional coronary
risk factors of the study cohort, were similar in men and
women in most respects (Table 1). However, previous MI was
more common in men than in women (chi-square 6.4, p 5
0.01), and family history of premature CAD was more preva-
lent in women than in men (chi-square 8.8, p 5 0.003). All
patients were receiving at least one antianginal medication,
and 21% of the whole study group were receiving lipid-
lowering treatment.
Distribution of angiographic scores and serum lipids. The
distribution of angiographic scores in the study cohort is
summarized in Table 2. Forty-eight patients (37%) had no
significant coronary stenosis ($70%), as defined by a vessel
score of 0; 27 patients (21%) had single-vessel disease, and the
remainder (42%) had double- or triple-vessel disease. Thirty-
two patients (25%) had angiographically normal coronary
arteries, as defined by an extent score of 0. Serum lipid and
lipoprotein concentrations in the study cohort are summarized
in Table 3. Overall, the median (interquartile range) Lp(a)
level was 252 mg/liter (64 to 697) (i.e., within the normal range
for healthy white subjects) (4). Twenty-six patients (19%) had
plasma Lp(a) concentrations below the limit of detection for
the assay (,50 mg/liter). There was no significant difference
between Lp(a) levels in men and women (270 mg/liter [56 to
783] vs. 242 mg/liter [77 to 653], respectively, p 5 0.94).
Similarly there was no significant difference in LDL levels
Table 1. Clinical Features of Study Groups
Men
(n 5 86)
Women
(n 5 43)
Age (yr) 60 6 10 62 6 10
Previous MI 37% 14%
CCS class
I 19% 10%
II 63% 64%
III 19% 26%
SBP (mm Hg) 135 6 22 136 6 22
DBP (mm Hg) 78 6 13 77 6 16
Hypertension 19% 22%
Family history of premature CAD 33% 62%
Smoking history
Current smoker 12% 7%
Ex-smoker 70% 55%
Nonsmoker 19% 38%
Previous CVA or PVD 7% 9%
BMI (kg/m2) 26.0 6 3.5 27.0 6 4.9
Data presented are mean value 6 SD or percent of patients. BMI 5 body
mass index; CAD 5 coronary artery disease; CCS 5 Canadian Cardiovascular
Society; DBP 5 diastolic blood pressure; CVA 5 cerebrovascular disease; MI 5
myocardial infarction; SBP 5 systolic blood pressure.
Table 2. Distribution of Coronary Scores
No. (%) of Patients
Vessel score*
0 48 (37.2%)
1 27 (20.9%)
2 29 (22.5%)
3 25 (19.4%)
Extent score*
0 32 (24.8%)
1–20 54 (41.8%)
21–40 33 (25.6%)
.40 10 (7.8%)
*See Methods.
Table 3. Serum Lipid and Lipoprotein Levels in Study Groups
All Patients
(n 5 129)
Men
(n 5 86)
Women
(n 5 43)
No CAD
(n 5 48)
(vessel score 0)
CAD
(n 5 81)
(vessel score $1) p Value
Total cholesterol (mmol/liter) 5.7 6 1.0 5.7 6 1.0 5.6 6 1.0 5.6 6 1.0 5.7 6 1.0 0.35
HDL cholesterol (mmol/liter) 1.0 6 0.4 0.9 6 0.3 1.3 6 0.4 1.2 6 0.4 1.0 6 0.4 0.01
LDL cholesterol (mmol/liter) 4.0 6 0.9 4.1 6 0.9 3.8 6 0.9 3.7 6 0.8 4.2 6 1.0 0.03
TGs (mmol/liter) 1.6 6 1.3 1.8 6 1.5 1.2 6 0.6 1.4 6 0.8 1.7 6 1.6 0.15
Lp(a) (mg/liter) 252 (64–697) 270 (56–783) 242 (77–653) 105 (56–366) 372 (87–884) 0.002
Data presented are mean value 6 SD or median (interquartile range). CAD 5 angiographic coronary artery disease; HDL 5 high density lipoprotein; LDL 5 low
density lipoprotein; Lp(a) 5 lipoprotein(a); TGs 5 triglycerides.
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between men and women. However, men had significantly
higher levels of triglycerides and lower levels of HDL choles-
terol than women (p , 0.0001 in both cases). Overall, the
mean LDL level in our study group was only mildly elevated
(4.0 6 0.9 mmol/liter) but was significantly lower in patients
who were receiving (n 5 27) than in those not receiving (n 5
102) lipid-lowering therapy (3.40 6 0.83 vs. 4.18 6 0.93
mmol/liter, respectively, p 5 0.0002).
Relation between serum lipids and angiographic scores.
Plasma Lp(a) levels were higher in patients with (vessel score
$1) than in those without significant stenoses (372 mg/liter [87
to 884] vs. 105 mg/liter [56 to 366], respectively, p 5 0.002)
(Table 3, Fig. 1). Serum LDL cholesterol concentration was
also significantly higher (4.2 6 1.0 vs. 3.7 6 0.8 mg/dl,
respectively, p 5 0.03) and HDL cholesterol levels significantly
lower (1.0 6 0.4 vs. 1.2 6 0.4 mg/dl, respectively, p 5 0.01) in
patients with than in those without significant coronary steno-
sis. Further analysis using extent scores to include the effect of
patients with mild angiographic disease yielded similar results.
Plasma Lp(a) concentrations were significantly higher in pa-
tients with an extent score $1 (n 5 97) than in those with an
extent score of 0 (n 5 32) (312 mg/liter [64 to 864] vs. 116
mg/liter [63 to 366], respectively, p 5 0.02). Likewise, serum
LDL cholesterol levels were significantly higher (4.1 6 0.98 vs.
3.68 6 0.84 mg/dl, respectively, p 5 0.04) and HDL cholesterol
concentrations significantly lower (0.99 6 0.36 vs. 1.25 6 0.46
mg/dl, respectively, p 5 0.01) in patients with mild or severe
CAD than in those with normal angiographic findings.
Gender differences in angiographic scores and plasma
Lp(a) levels. The mean number of diseased vessels was higher
in men than in women (1.5 6 1.1 vs. 0.7 6 1.0, p , 0.0001).
Similarly, the average extent score was significantly higher in
men than in women (15.5 [8 to 29] vs. 3.0 [0 to 14], respectively,
p , 0.0001). The differences between plasma Lp(a) levels in
patients with and without significant stenoses (defined by a
vessel score $1 [Fig. 1]) appeared to be largely due to the
difference observed in women (625 mg/liter [376 to 1,044] vs.
108 mg/liter [56 to 373], respectively, p 5 0.0003). By compar-
ison, the difference in Lp(a) levels observed in men alone
failed to achieve statistical significance (320 mg/liter [60 to 875]
vs. 103 mg/liter [54 to 366], respectively, p 5 0.11). Further
independent analysis of men and women using an extent score
$1 to define the presence of angiographic CAD (i.e., including
patients with mild angiographic disease) produced similar
results. The difference observed in women was statistically
significant (570 mg/liter [127 to 823] vs. 133 mg/liter [50 to
373], p 5 0.01), whereas that observed in men was not (285
mg/liter [50 to 875] vs. 113 mg/liter [88 to 366], p 5 0.26).
Extent of angiographic CAD, coronary occlusions and
previous MI. Analysis of patients with significant stenoses
according to vessel score (Fig. 2) demonstrated that Lp(a)
levels did not differ significantly among patients with one-, two-
and three-vessel disease (p 5 0.30). Similarly, when patients
with mild or severe disease (extent score $1) were classified
into three groups according to extent of disease (1 to 20, 21 to
40, .40), there was no significant difference in Lp(a) levels
between the groups (p 5 0.13). In patients with significant
angiographic CAD (vessel score $1), there was no significant
difference in Lp(a) levels between those with (n 5 41) and
those without (n 5 40) occlusions (415 mg/liter [109 to 1,019]
vs. 350 mg/liter [76 to 785], respectively, p 5 0.63). However, in
patients with significant coronary stenoses ($70%), a statisti-
cal trend appeared, suggesting that plasma Lp(a) levels were
higher in those with (n 5 31) than in those without (n 5 50) a
previous history of acute MI (415 mg/liter [199 to 1,023] vs. 330
mg/liter [60 to 720], respectively, p 5 0.12). Furthermore, when
angiographic CAD was defined by an extent score $1 (i.e.,
including patients with mild disease), the difference between
patients with (n 5 34) and without (n 5 63) a previous MI
achieved statistical significance (525 mg/liter [185 to 1,075] vs.
252 mg/liter [58 to 639], respectively, p 5 0.02).
Multivariate analysis. Multiple logistic regression analysis
including age, gender, hypertension, smoking and lipid vari-
ables [Lp(a), LDL, HDL and triglycerides] was performed
using an extent score $1 to define the presence of angio-
graphic CAD. When all patients were included in the model,
Figure 1. Plasma Lp(a) levels were significantly higher in patients with
(shaded boxes) than in those without (open boxes) significant angio-
graphic CAD. When patients were classified according to gender, this
difference achieved statistical significance in women but not in men.
Figure 2. Subset analysis of patients with angiographic CAD according
to vessel score did not indicate a significant difference between Lp(a)
levels in patients with one-, two- or three-vessel disease.
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Lp(a) concentration was the only lipid variable that achieved
statistical significance as an independent predictor of CAD
(Table 4). However, when patients receiving lipid-lowering
therapy (n 5 27) were excluded, both LDL cholesterol and
triglyceride levels became significant independent predictors of
CAD, and plasma Lp(a) concentration no longer achieved
significance within the model. In both analyses, male gender
and a history of smoking were independently predictive of
CAD. A further multivariate analysis with CAD defined as the
presence of any $50% stenosis (i.e., vessel score $1) yielded
similar results. When all patients were included in this analysis,
plasma Lp(a) concentration was the only lipid variable inde-
pendently predictive for CAD [odds ratio [OR] 9.1, 95%
confidence interval [CI] 2.0 to 42.1, p 5 0.006). When patients
receiving lipid-lowering treatment were excluded, Lp(a) con-
centration remained a significant predictor of CAD (OR 10.4,
95% CI 1.1 to 102.9, p 5 0.05), whereas neither LDL (OR 5.3,
95% CI 0.8 to 33.4, p 5 0.08) nor triglyceride level (OR 0.3,
95% CI 0.02 to 0.7, p 5 0.12) achieved significance. HDL
concentration was not significantly predictive of CAD as
defined by vessel or extent score in any of the analyses.
Discussion
Many previous studies examining the relation between
plasma Lp(a) levels and angiographic CAD have been limited
because of the relative lack of clinical data and the underrep-
resentation of women. In the present investigation, we studied
a consecutive series of well characterized white patients who
had been admitted for routine coronary angiography for
symptoms consistent with a diagnosis of chronic stable angina.
Clinical variables, including conventional coronary risk factors,
had been well characterized in all cases. Female patients were
well represented (33%) in this series and had baseline clinical
characteristics similar to those of the male patients.
Lp(a) and presence of angiographic CAD. The results of
our study indicate that in patients with chronic stable angina,
plasma Lp(a) levels are significantly higher in those with than
in those without CAD. Analysis of all patients, including those
receiving lipid-lowering therapy, was justified because the
number of patients receiving lipid-lowering therapy in the
study group was relatively small (21%), and the extent of their
disease at angiography would tend to reflect the accumulated
effects of their lipid environment before and after initiation of
lipid-lowering therapy. Furthermore, Lp(a) levels are not
substantially modified by standard lipid-lowering therapy (4).
Our results are consistent with previous studies that have
demonstrated an association between raised plasma Lp(a) and
the presence of CAD (7,8,15–18,27–30) and highlights the
atherogenic potential of Lp(a) (31). The mean LDL level in
our study group was only mildly elevated but was significantly
higher in patients with than in those without CAD. This
difference remained significant before and after exclusion of
those receiving lipid-lowering therapy. It is interesting to
compare the results of our multiple regression analysis with the
findings of the Familial Atherosclerosis Treatment Study
(FATS) study (32), which assessed the effects of lipid-lowering
interventions on angiographic disease progression in hypercho-
lesterolemic men. The FATS results indicated that a .10%
reduction of elevated plasma LDL levels offset the proathero-
genic effects of raised Lp(a) levels, even when the latter
remained unmodified. Conversely, plasma Lp(a) concentration
remained strongly correlated with angiographic progression in
patients with #10% reduction in plasma LDL levels. The mean
LDL level in our study group was relatively low compared with
that in the FATS study (4.0 6 0.9 vs. 5.0 6 1.2 mmol/liter,
respectively) (32). In our study, plasma LDL levels were
significantly lower in patients with (n 5 27) than in those
without (n 5 102) lipid-lowering therapy (3.4 6 0.8 vs. 4.2 6
0.9 mmol/liter, respectively, p 5 0.0002). Our multiple logistic
regression analysis including all patients indicated that Lp(a)
level was the only lipid variable that was an independent risk
factor for the presence of any angiographic disease (extent
score $1). This finding is consistent with a similar analysis of
baseline disease severity performed in the FATS study (32).
However, after exclusion of patients receiving lipid-lowering
therapy, both LDL cholesterol and triglyceride levels became
significant predictors of angiographic CAD within our model,
Table 4. Adjusted Odds Ratio for Risk of Patients Having Angiographic Coronary Artery Disease
(extent score $1)*
Explanatory
Variable
All Patients (n 5 129)
Patients Not Receiving Lipid-
Lowering Therapy (n 5 102)
OR (CI) p Value OR (CI) p Value
Lp(a) 11.8 (90.8–1.54) 0.02 4.76 (101–0.22) 0.33
TGs 0.24 (1.07–0.06) 0.06 0.12 (0.69–0.02) 0.02
LDL 2.75 (14.0–0.54) 0.23 9.99 (87.4–1.14) 0.04
HDL 0.28 (1.32–0.06) 0.11 0.20 (1.71–0.02) 0.14
Age 5.12 (25.8–1.01) 0.05 2.96 (21.2–0.41) 0.28
Female gender 0.16 (0.59–0.04) 0.01 0.10 (0.55–0.02) 0.01
Smoking 5.80 (23.0–1.46) 0.01 6.27 (29.4–1.34) 0.02
Hypertension 0.65 (2.34–0.18) 0.51 0.20 (1.21–0.03) 0.08
*Odds ratio (OR) (95% confidence interval [CI]) given to three significant figures; odds ratio for continuous variables
defined according to ratio of risk between 10th and 90th percentiles.
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whereas Lp(a) was no longer significant. Although at first
glance this finding appears to conflict with the results of the
FATS trial, the outcome variable in our analysis was the
presence or absence of angiographic disease compared with
angiographic disease progression in the FATS trial. Further-
more, plasma LDL levels in our patients receiving lipid-
lowering therapy had been elevated before the initiation of
therapy, and most had been receiving lipid-lowering therapy
for ,1 year. With this in mind, our findings are consistent with
the conclusion of the FATS investigators (32) that the
proatherogenic potential of Lp(a) may be dependent on
synergism with elevated plasma LDL cholesterol levels. Nev-
ertheless, further multivariate analysis, including only those
patients with angiographic stenoses $70% (i.e., excluding
patients with mild disease), indicated that Lp(a) levels remain
an independent predictor of CAD even after the exclusion of
patients receiving lipid-lowering therapy. This finding suggests
that high Lp(a) levels may independently contribute to the
evolution of severe angiographic stenoses.
Plasma Lp(a), extent of angiographic CAD and presence of
coronary occlusions. The results of our investigation did not
indicate any significant difference between plasma Lp(a) levels
in subsets of patients with significant CAD classified according
to the number of diseased vessels or the extent of angiographic
disease. These findings are in agreement with those of other
investigators (19,20) who failed to demonstrate a correlation
between Lp(a) levels and angiographic vessel score. We also
found that in patients with $70% angiographic stenoses, there
was no significant difference in Lp(a) levels between those with
and without coronary occlusions. However, a strong statistical
trend was demonstrated, suggesting that Lp(a) levels were
higher in patients with CAD and a previous MI than in those
with CAD but no previous MI. When this analysis was
repeated using an extent score $1 to define CAD (i.e.,
including patients with mild disease), the difference between
patients with and without an acute MI achieved full statistical
significance (p 5 0.02). These findings indicate that in addition
to the positive relation between Lp(a) levels and angiographic
CAD, a relation also exists between Lp(a) levels and the
incidence of MI. This concept suggests that high Lp(a) levels
may predispose to plaque disruption and thrombogenesis—the
pathogenetic basis of MI. These findings are also in agreement
with previous studies (8,15,16) that indicated that raised
plasma Lp(a) levels correlate with a history of previous MI.
Prospective studies have also suggested that elevated Lp(a)
levels are a risk factor for subsequent MI (10–14), although
other studies (33,34) have failed to confirm these findings.
Lp(a) as a risk factor in women. Our data indicated that
the difference between Lp(a) levels in patients with and those
without angiographic CAD was largely due to the difference
observed in women. This finding is consistent with those of
Stiel et al. (20) and supports the existence of important gender
differences with regard to Lp(a) and CAD. Few other studies
have analyzed the relation between CAD and Lp(a) levels in
women. Interestingly, Labeur et al. (16) in a study of 1,054
patients, including 323 women, also observed a significant
multivariable adjusted odds ratio for the presence of CAD in
women but not men. Therefore, it appears that Lp(a) plasma
levels may have particular significance with regard to the
evolution of CAD in women.
Pathogenic mechanisms by which Lp(a) may contribute to
the evolution of angiographic CAD and MI. Our findings
suggest that high Lp(a) levels predispose to the evolution of
CAD and MI, although the exact mechanisms remain specu-
lative. Lp(a) can transverse the endothelium and accumulate in
the arterial intima (35), where it may be taken up by macro-
phages (36). By virtue of its marked homology with plasmino-
gen (2), apo(a) interacts directly with plasminogen binding
sites, thereby interfering with the fibrinolytic process (3,37).
Studies in transgenic mice models expressing apo(a) have
demonstrated that apo(a) inhibits plasminogen activation in
vivo (38). This result is consistent with the known association
between high Lp(a) levels, clot formation and impaired spon-
taneous thrombolysis (1,3). Inhibition of plasminogen activa-
tion blocks the plasmin-dependent activation of transforming
growth factor-beta (39), an autocrine inhibitor of vascular
smooth muscle cell proliferation. These phenomena may rep-
resent the mechanisms whereby raised Lp(a) predisposes to
atherosclerotic CAD and MI.
Conclusions. The results of our study indicate that ele-
vated plasma Lp(a) is an independent risk factor for angio-
graphic CAD and MI in patients with chronic stable angina
and may have particular significance in women.
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